Join to View Full Profile
736 Cambridge St.Brighton, MA 02135
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Julia Hayes, MD is an oncologist in Brighton, Massachusetts. She is currently licensed to practice medicine in Massachusetts and New York. She is affiliated with Boston Medical Center - Brighton and is an Instructor in Medicine at Dana-Farber Cancer Institute.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2004 - 2007
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2001 - 2004
Harvard Medical SchoolClass of 2001
Certifications & Licensure
MA State Medical License 2004 - 2026
NY State Medical License 2004 - 2005
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Longitudinal Medical Record, Partners Healthcare System, 2013-2015
- CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2013-2015
Publications & Presentations
PubMed
- 17 citationsDecision regret, adverse outcomes, and treatment choice in men with localized prostate cancer: Results from a multi-site randomized trialDonna L. Berry, Fangxin Hong, Traci M. Blonquist, Barbara Halpenny, Niya Xiong
Urologic Oncology. 2021-08-01 - 38 citationsDecision Support with the Personal Patient Profile-Prostate: A Multicenter Randomized TrialDonna L. Berry, Fangxin Hong, Traci M. Blonquist, Barbara Halpenny, Christopher P. Filson
The Journal of Urology. 2018-01-01 - 5 citationsEvaluating an Elevated Screening PSA TestMichael J. Barry, Julia H. Hayes
JAMA. 2015-11-17
Press Mentions
Observation Is Safe, Cost-Saving in Low-Risk Prostate Cancer, Study SuggestsFebruary 10th, 2016
Low-Risk Prostate Cancer, Observation Safe and Cost-EffectiveFebruary 10th, 2016
